Ligands for peroxisome proliferator-activated receptor ␥ (PPAR␥) induce apoptosis and exert antiproliferative effects on several carcinoma cell lines. The present study investigates the expression of PPAR␥ and the possibility that agonists for PPAR␥ also inhibit the growth of human thyroid carcinoma cells. We examined this hypothesis using six cell lines, designated BHP thyroid carcinoma cells, which originated from patients with papillary thyroid carcinoma. RT-PCR analysis revealed that the thyroid carcinoma cell lines BHP2-7, 7-13, 10 -3, and 18 -21 express PPAR␥. More PPAR␥ was expressed in carcinoma than in adjacent normal thyroid tissue in three of six samples of human papillary carcinoma of the thyroid.
noma cell lines that expressed PPAR␥. Under low serum conditions, ligands for PPAR␥ induced condensation of the nucleus and fragmentation of chromatin into nucleosome ladders. These findings indicate that the death of thyroid carcinoma cells is a form of apoptosis.
To investigate the molecular mechanism of the apoptosis, we assessed expression of the apoptosis-regulatory genes bcl-2, bax, and c-myc. Troglitazone significantly increased the expression of c-myc messenger RNA but had no effect on the expression of bcl-2 and bax in thyroid carcinoma cells. These results suggest that, at least in part, the induction of apoptosis in human papillary thyroid carcinoma cells may be due to an increase of c-myc.
Troglitazone (500 mg/kg⅐day) significantly inhibited tumor growth and prevented distant metastasis of BHP18 -21 tumors in nude mice in vivo.
Taken together, these results suggest that PPAR␥ agonist inhibit cell growth of some types of human thyroid cancer. (J Clin Endocrinol Metab 86: 2170 -2177, 2001) H UMAN PAPILLARY CARCINOMA has a relatively good prognosis (1, 2) . The primary disease associated with differentiated papillary thyroid carcinoma is usually removed by surgery and by 131 I radiation, which are potentially curative (3) (4) (5) . On the other hand, during the course of tumor progression, the morphological and functional characteristics of differentiated thyroid carcinoma may disappear. In dedifferentiated thyroid carcinoma, the expression of thyroid-specific genes, namely thyroglobulin, thyroid peroxidase, and TSH receptor is diminished (6, 7) . Clinically, several papillary thyroid carcinomas lose the ability to accumulate radioiodine. This phenomenon is associated with a worse prognosis and prevents effective treatment. The shortage of curative therapies for undifferentiated thyroid carcinoma has resulted in a demand to rapidly develop novel therapies.
The peroxisome proliferator-activated receptor ␥ (PPAR␥) belongs to the nuclear hormone receptor superfamily, and it plays an important role in the differentiation of adipocytes (8, 9) . Ligands for PPAR␥ induces apoptosis and exert antiproliferative effects on several carcinoma cell lines (10 -13) . In the present study, we examined the expression of PPAR␥ and the effects of PPAR␥ ligands on the growth of human papillary thyroid carcinoma cells. We also investigated the ability of PPAR␥ agonist to inhibit the growth of thyroid carcinoma in vivo.
Materials and Methods

Cells and samples
All thyroid papillary carcinoma cell lines (BHP2-7, 7-13, 10 -3, 14 -9, 18 -21, and 19 -24) were maintained in RPMI 1640 medium supplemented with 10% FBS in a 5% CO 2 -95% air atmosphere at 37 C, as described previously (14, 15) . Neoplastic human thyroid tissues [papillary carcinoma (n ϭ 6), follicular adenoma (n ϭ 2)] and adjacent normal thyroid tissue (n ϭ 4) were surgically resected with the informed consent of the patients.
Chemicals
Troglitazone was provided by Sankyo Co., Ltd. (Tokyo, Japan). Pioglitazone was provided by Takeda Pharmaceutical Co. (Osaka, Japan). All other reagents were purchased from Sigma (St. Louis, MO).
RT-PCR
Total RNAs were prepared using acid-guanidium thiocyanate phenol chloroform (16) . RNA (10 g) was reverse transcribed with Rous-associated virus reverse transcriptase (Takara Shuzo Co., Kyoto, Japan) at 42 C for 60 min in a 40-L mixture in the presence of random primer. One microliter of a reverse-transcribed mixture was amplified by PCR. The primers for PPAR␥ were 5Ј-TCTGGCCCACCAACTTTGGG-3Ј (nucleotides 113-132, upstream) and 5Ј-CTTCACAAGCATGAACTCCA-3Ј (nucleotides 453-472, downstream) (17) . RT-PCR efficiency was confirmed in all samples by amplifying human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the primers (sense) 5Ј-AACGTGT-CAGTGGTGGTGGACCT-3Ј (nucleotides 775-794) and (antisense) 5Ј-ATGGCCCACATGGCCTCCAA-3Ј (nucleotides 1042-1061) (18) . The primers using for amplification of PPAR␥ and GAPDH were designed to span the 2nd intron and 8th intron, respectively. PCR products were sequenced using a Cycle Sequencing Kit (Takara Shuzo Co.). 
Cell counting
Cells were seeded at a density of 1 ϫ 10 4 cells per well in 24-well tissue culture plates in 1.0 mL RPMI 1640 medium supplemented with 10% FBS with or without the indicated factors. The medium was changed every other day. After 72 h in an atmosphere of 5% CO 2 -95% air at 37 C, cells were detached from plates by incubation with 500 L PBS containing 100 mg trypsin and 1 mmol/L EDTA. Cells were counted using a hemocytometer.
Measurement of apoptosis
BHP18 -21 thyroid carcinoma cells cultured on cover slips were incubated with or without 10 mol/L troglitazone in RPMI 1640 medium supplemented with 0.1% FBS for 24 h. The cells were fixed with 1% glutaraldehyde and stained with 1 mmol/L bisBenzimide (Hoechst 33342; Sigma). Apoptotic bodies were observed by fluorescent microscopy.
DNA fragmentation was visualized by autoradiography. Confluent cells in culture dishes were incubated with indicated concentration of troglitazone in RPMI 1640 medium supplemented with 0.1% or 10% FBS, then harvested at various times. DNA was extracted, 3Ј-end labeled, and resolved by electrophoresis as described (19) .
Northern blotting
Total RNA (20 g) was denatured by incubation with 50% formamide and resolved by electrophoresis through a 1% agarose gel containing 6.0% formaldehyde and 20 mmol/L morpholinepropane sulfonic acid buffer. RNA was then blotted onto nitrocellulose membranes. Equal loading per lane was verified by ethdium bromide staining of 18S and 28S ribosomal RNA, which was visualized and photographed under ultraviolet illumination. After prehybridization for 4 h at 42 C in 50% deionized formamide containing 5ϫ SSC, 50 mmol/L sodium phosphate (pH 6.7), 40 mg/mL denatured salmon sperm DNA, and 4ϫ Denhardt's solution (50ϫ Denhardt's solution, 10 g/L polyvinylpyrrolidone, 10 g/L Ficoll, and 10 g/L BSA), the membranes were hybridized with 32 Plabeled complementary DNA (cDNA) overnight at 42 C. cDNAs for human c-myc, bax, and bcl-2 were labeled with [␣-
32 P]deoxy-cytidine triphosphate using a random primer labeling kit (Takara Shuzo Co.). Blots were washed in 2ϫ SSC, 0.1% SDS three times at room temperature for 10 min, then in 0.1ϫ SSC, 0.1% SDS three times at 50 C for 20 min. Northern analysis was repeated three times. The membranes were exposed to an imaging plate, and densitometric analysis of results was performed using a Bas 2000 image analyzer (Fuji Photo Film Co., Ltd., Tokyo, Japan).
Murine studies in vivo
BHP18 -21 thyroid carcinoma cells (5 ϫ 10 6 ) in 0.1 mL PBS were injected sc into the trunk of 8 male BALB/c nude mice at 6 weeks of age.
Treatment began on the day after injection and was continued for 8 weeks. Control mice (4 mice per group) received solvent (dimethylsulfoxide) only or troglitazone (500 mg/kg⅐day) orally by gavage. Tumors were measured every week, and size was calculated using the following formula: A (length) ϫ B (width) ϫ C (height) ϫ 0.5236. After 8 weeks, nude mice were killed and distant metastasis was searched macroscopically. Tumor, liver, lung, and spleen were fixed and stained for histological analysis. All experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. The experimental protocol was approved by the Animal Care and Use Committees of Yamanashi Medical University.
Statistical analysis
Samples were examined in triplicate wells. Data are presented as means Ϯ sd. Statistical analysis was performed by one-way ANOVA. Statistical significance was set at P less than 0.05. Scheffé's F post hoc method detected significant differences between group means.
Results
Expression of PPAR␥ in thyroid carcinoma cells
We studied the expression of PPAR␥ in six human papillary thyroid carcinoma cells using RT-PCR and specific primers. Amplification by RT-PCR yielded a DNA fragment of the predicted size and revealed PPAR␥ messenger RNA (mRNA) in four of six papillary thyroid carcinoma cell lines, namely BHP2-7, BHP7-13, BHP10 -3, and BHP18 -21 ( Fig. 1) . In contrast, the human papillary carcinoma cell lines BHP14 -9 and BHP19 -24 did not express PPAR␥ mRNA.
The expression of PPAR␥ mRNA in human thyroid tissues was also investigated. We analyzed cDNAs prepared from 12 human thyroid tissues (6 papillary carcinoma, 4 normal thyroid, and 2 adenomas) using RT-PCR. Of the 6 papillary carcinoma tissues, 3 expressed PPAR␥ mRNA. In these samples, PPAR␥ mRNA was not expressed in adjacent normal thyroid tissues (Fig. 2) . Furthermore, PPAR␥ mRNA was not expressed in any other normal or adenoma thyroid tissue investigated. (Fig. 3) . Under low serum conditions (0.1% FCS), troglitazone (10 mol/L) reduced [ 3 H]thymidine incorporation into BHP2-7, 7-13, 10 -3, and 18 -21 cells to a level below 1% of the control. In the presence of troglitazone (10 mol/L) in 0.1% FCS, cells became deformed and detached within 24 h. Wy14,643 (10 mol/L) and all-trans-retinoic acid (10 mol/L) did not reduce [
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3 H]thymidine incorporation into BHP2-7, 14 -9, and 18 -21 cells (data not shown).
Effects of PPAR␥ agonists on the growth of human thyroid carcinoma cell lines
Troglitazone (10 mol/L) and BRL 49653 (10 mol/L) significantly decreased numbers of BHP2-7, 7-13, 10 -3, and 18 -21 thyroid carcinoma cells compared with control values (P Ͻ 0.05) ( Table 1 ). In contrast, these agents did not affect the number of BHP14 -9 and 19 -24 thyroid carcinoma cells that did not express PPAR␥. 15-deoxy-⌬12,14-prostaglandin J2 (prostaglandin J2; 1 g/mL) significantly inhibited the growth of BHP7-13 and BHP18 -21 cells, but not BHP14 -9 cells. Wy14,643 (10 mol/L), a PPAR␣ agonist, did not influence the growth of any thyroid carcinoma cell lines examined. Figure 4 , A and B, shows the morphological changes induced by troglitazone. BHP18 -21 cells in logarithmic growth phase were transferred into 0.1% FCS RPMI 1640 medium with or without 10 mol/L troglitazone. Cells incubated with troglitazone lost cell-to-cell contact. Fluorescent staining revealed fragmentation and condensation of the nucleus (Fig. 4, C and D) .
Detection of apoptotic cells
DNA extracted from BHP18 -21 cells treated for 4 h with 10 mol/L troglitazone in 0.1% FCS showed evidence of degradation, with internucleosomal DNA laddering, which is associated with apoptotic cell death (Fig. 5A) . In contrast, 10 mol/L troglitazone in 0.1% FCS did not induce DNA fragmentation on BHP14 -9 thyroid carcinoma cells that did not express PPAR␥. Troglitazone in 0.1% FCS induced DNA fragmentation on BHP18 -21 cell in a dose-dependent manner. However, under 10% FCS conditions, even 10 mol/L troglitazone did not apparently induce DNA fragmentation (Fig. 5B) . To induce DNA fragmentation on BHP18 -21 cells under 10% FCS condition, more than 100 mol/L troglitazone was required (data not shown). 
Northern blots
To investigate the molecular mechanism of apoptosis, we evaluated the expression levels of apoptosis-regulated genes in BHP18 -21 cells using c-myc, bcl-2, and bax cDNA as probes. Troglitazone in 0.1% FCS significantly and dosedependently increased c-myc mRNA levels in BHP18 -21 cells. Densitometric data showed 10 mol/L troglitazone in 0.1% FCS increased c-myc mRNA levels by 3.0-fold compared with the control (Fig. 6A) . However, in 10% FCS 10 mol/L troglitazone increased c-myc mRNA level only by 1.3-fold of control. Figure 6B shows the time course of c-myc mRNA expression. Troglitazone (10 mol/L) in 0.1% FCS increased levels of c-myc mRNA within 2 h and continued to do so for 12 h. In contrast, expression levels of bcl-2 and bax genes were not affected by 10 mol/L troglitazone.
Antitumor effect in vivo
We evaluated the antitumor effect of troglitazone in vivo using BHP18 -21 thyroid carcinoma cells in BALB/c nude mice. Histological analysis of BHP18 -21 tumors from untreated mice revealed undifferentiated thyroid carcinoma tissue and distant metastasis of tumor in the liver (Fig. 7, A  and B) . Troglitazone visibly inhibited the growth of BHP18 -21 tumors (Fig. 7, C and D) . 
Discussion
We studied six human papillary thyroid carcinoma cell lines. The RT-PCR data showed that four of six thyroid carcinoma cell lines expressed PPAR␥ mRNA. Interestingly, four PPAR␥-positive thyroid carcinoma cells could form a tumor, if these cells were transplanted to nude mice. In contrast, PPAR␥-negative cells could not form a tumor in nude mice. These observations suggest that PPAR␥ expression might be related to tumor progression. We also demonstrated expression of PPAR␥ mRNA in three of six human papillary carcinoma tissues. It is noteworthy that PPAR␥ mRNA was undetectable in the adjacent normal thyroid tissues. Additionally, PPAR␥ mRNA was not expressed in any thyroid adenoma tissues examined. These findings suggest that the prominent expression of PPAR␥ mRNA is a feature of thyroid carcinoma. Elstner et al. (10) reported that breast cancer cells express a higher level of PPAR␥ protein than normal breast epithelial cells. Our data agree with these findings. However, we could not find any histological or clinical difference between PPAR␥-positive and -negative thyroid papillary carcinoma. Further study is required to understand the relationship between PPAR␥ expression and the growth and tumorigenecity of thyroid neoplasms.
Because PPAR␥ was expressed in four thyroid carcinoma cell lines, we examined the effects of PPAR␥ agonists on these lines. The growth of these four thyroid papillary carcinoma cells was inhibited by troglitazone or BRL 49653, synthetic ligands for PPAR␥, and prostaglandin J2, a natural ligand for PPAR␥. In contrast, PPAR␥ agonists did not inhibit the growth of PPAR␥-negative thyroid carcinoma cells. Furthermore, Wy14,643 or all-trans-retinoic acid, a PPAR␣ agonist or retinoic acid receptor agonist, did not affect the growth of any thyroid carcinoma cells examined. These results suggest that the inhibition of thyroid carcinoma cells is specifically mediated through PPAR␥.
Troglitazone inhibits growth by inducing apoptosis in several carcinoma cells (10, 11, 13) . We examined the notion that apoptosis is induced during the inhibition of thyroid carcinoma cell growth. We demonstrated that DNA from BHP18 -21 cells undergoing death induced by troglitazone in 0.1% FCS showed chromatin fragmentation into nucleosome ladders. Furthermore, morphological observation revealed that troglitazone caused nuclear condensation and fragmentation. These findings indicate that troglitazone induced apoptosis and decreased the number of thyroid carcinoma cells.
The mechanism by which PPAR␥ agonists induce apoptosis remains unknown. Many genes are involved in the progression of apoptosis. To investigate the molecular mechanism underlying the apoptosis of thyroid carcinoma cells, we evaluated apoptosis-related gene expression. We found that troglitazone dose-dependently increased c-myc protooncogene mRNA. Furthermore, serum deprivation potentiated the effect of troglitazone on the induction of c-myc mRNA and apoptosis. In marked contrast, the expression levels of bcl-2 or bax, which are survival and apoptotic genes, respectively (20, 21) , were not affected by troglitazone. The results of dose-response studies lead us to conclude that apoptosis by troglitazone may be, at least in part, due to increase of c-myc. The inappropriate expression of c-Myc induces or sensitizes cells to apoptosis (22) . Evan et al. (23) reported that the overexpression of c-myc rendered fibrobrasts prone to cell death on serum deprivation and led to the induction of apoptosis by various means. Our findings are in agreement with these observations. However, further study is required to reveal the role of c-myc in apoptosis.
In 10% FCS condition, 10 mol/L troglitazone reduced [ 3 H]thymidine incorporation and cell number of PPAR␥-positive thyroid carcinoma cells. However, DNA fragmentation was not clearly observed. One of the possibilities of these inconsistencies might be due to the sensitivity of DNA fragmentation assay. Another possibility is that troglitazone might inhibit the growth of thyroid carcinoma cells by other mechanism than apoptosis. To clarify this subject, we are trying to identify the gene, which is responsible for the growth inhibition by troglitazone in 10% FCS using differential display technique.
Our animal studies revealed that troglitazone also inhibits the growth of thyroid carcinoma cells in vivo. Mice inoculated with tumor cells and given only solvent developed sc tumors with distant metastasis in the liver. In contrast, mice treated with troglitazone did not develop tumors and distant metastasis. The doses of troglitazone applied in the present study (500 mg/kg⅐day) is higher than human dose and dose titration experiment must be required. However, it is noteworthy that troglitazone inhibits tumor growth without affecting the mean blood chemistries and hematopoietic values (11) . Pioglitazone, another synthetic thiazolidinedione, also exerts growth inhibitory effect on BHP18 -21 cells (data not shown). Troglitazone is no longer widely used, but Pioglitazone is used to treat patients with type 2 diabetes mellitus. Although further study using different animal models is required to clarify antitumor effects, thiazolidinedione compounds might be useful as therapeutic agents in treating thyroid carcinoma that expresses PPAR␥.
The present study examined four thyroid carcinoma cell lines that expressed PPAR␥ mRNA. These PPAR␥-positive thyroid carcinoma cell lines express Pax8 and/or TTF1, but not thyroid-specific proteins such as thyroglobulin, thyroid peroxidase, TSH receptor, and Na/I symporter (14, 15) . Therefore, these cell lines might be considered models of dedifferentiated papillary carcinoma. PPAR␥ agonists exerted antiproliferative effects on these dedifferentiated cells. Thus, PPAR␥ agonists might have therapeutic benefit even in the treatment of undifferentiated thyroid carcinoma that does not express thyroid-specific proteins.
In summary, we showed that PPAR␥ is expressed by four thyroid carcinoma cell lines and several thyroid carcinoma tissues. We demonstrated that PPAR␥ agonists inhibit growth and induce apoptosis in these cell lines and that troglitazone inhibits the growth of thyroid carcinoma cells in vivo. These findings suggest that PPAR␥ agonists may be useful agents with which to treat thyroid cancer.
